Message Font: Serif | Sans-Serif
No. of Recommendations: 0
Excellent CMG write-up KitKat.
I'll add that if you back out the $5.93 in cash the difference is A an B shares is even wider, with B selling for 80%. As B shares are more valuable due to voting rights this is yet another nail in EMT.

Biota Here is my product and pipeline summary sheet
three main products in the pipeline.

In 2008, 50% of revenue came from Relenza, 40% from collaboration (milestones etc), 8% from interest and 2% from diagnostics (which is shrinking).

GSK have not informed Biota of any Relenza targets this yer, so Biota are giving no guidance, hence the opportunity/risk. The market seems to be completely discounting any Relenza income and not giving much value to the pipeline.

My latest ramblings on Biota are here

My calculations were are on the other tab of the spreadsheet.

EV of less than AUD$28M while EXEL has EV of $431M. One is generating profits and cash flow while the other is speculation.

I'm now long Biota.
Print the post  


Live Video Event Monday!
The GP team is hosting a live video event on Monday at 4 p.m. ET. Don't worry if you can't make it — we'll have a replay and a transcript. Click for more!
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.